Suppr超能文献

基于结构的虚拟筛选发现新型PKMYT1抑制剂。

Structure-based virtual screening discovers novel PKMYT1 inhibitors.

作者信息

Zhang Haoyu, Yu Jinyu, Yang Ziheng, Guo Zhiqiang, Liu Rui, Qin Qiaohua, Sun Yixiang, Liu Nian, Gao Zixuan, Zhao Dongmei, Cheng Maosheng

机构信息

Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang Pharmaceutical University Shenyang 110016 China

School of Pharmaceutical Engineering, Shenyang Pharmaceutical University Shenyang 110016 China.

出版信息

RSC Med Chem. 2024 Aug 6;15(9):3114-3124. doi: 10.1039/d4md00389f. eCollection 2024 Sep 19.

Abstract

PKMYT1, a member of the WEE family, plays a crucial role in the cell cycle by specifically phosphorylating CDK1-CyclinB at Tyr15 and Thr14. Recent investigations have revealed that the amplification of CCNE1 and the inhibition of PKMYT1 kinase collectively result in synthetic lethality, further indicating that PKMYT1 is promising as an effective target for tumor therapy. Existing PKMYT1 inhibitors are mostly derivatives of RP-6306 or pan-inhibitors, limiting their further development. Herein, we conducted virtual screening of a natural product library, and enzyme experiments demonstrated that EGCG, GCG, and luteolin exhibited potent inhibitory activities with IC values of 0.137 μM, 0.159 μM, and 1.5 μM, respectively. Subsequently, analysis of the hit compounds and RP-6306, using different molecular simulation methods, revealed that stable hydrogen bonds with Asp251 and Glu157 in the DFG region were vital for binding to PKMYT1, more so than hydrogen bonds in the hinge and loop regions.

摘要

PKMYT1是WEE家族的一员,通过特异性磷酸化CDK1 - 细胞周期蛋白B的Tyr15和Thr14位点,在细胞周期中发挥关键作用。最近的研究表明,CCNE1的扩增和PKMYT1激酶的抑制共同导致合成致死性,进一步表明PKMYT1有望成为肿瘤治疗的有效靶点。现有的PKMYT1抑制剂大多是RP - 6306的衍生物或泛抑制剂,限制了它们的进一步开发。在此,我们对一个天然产物库进行了虚拟筛选,酶实验表明,表没食子儿茶素没食子酸酯(EGCG)、没食子儿茶素(GCG)和木犀草素表现出强效抑制活性,IC值分别为0.137 μM、0.159 μM和1.5 μM。随后,使用不同的分子模拟方法对命中化合物和RP - 6306进行分析,结果显示,与DFG区域的Asp251和Glu157形成稳定的氢键对于与PKMYT1结合至关重要,比铰链区和环区的氢键更为重要。

相似文献

1
Structure-based virtual screening discovers novel PKMYT1 inhibitors.基于结构的虚拟筛选发现新型PKMYT1抑制剂。
RSC Med Chem. 2024 Aug 6;15(9):3114-3124. doi: 10.1039/d4md00389f. eCollection 2024 Sep 19.

本文引用的文献

4
PKMYT1 inhibits lung adenocarcinoma progression by abrogating AKT1 activity.PKMYT1通过消除AKT1活性来抑制肺腺癌进展。
Cell Oncol (Dordr). 2023 Feb;46(1):195-209. doi: 10.1007/s13402-022-00744-y. Epub 2022 Nov 9.
5
Targeting replication stress in cancer therapy.针对癌症治疗中的复制应激。
Nat Rev Drug Discov. 2023 Jan;22(1):38-58. doi: 10.1038/s41573-022-00558-5. Epub 2022 Oct 6.
7
CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition.CCNE1 扩增与 PKMYT1 激酶抑制协同致死。
Nature. 2022 Apr;604(7907):749-756. doi: 10.1038/s41586-022-04638-9. Epub 2022 Apr 20.
8
OPLS4: Improving Force Field Accuracy on Challenging Regimes of Chemical Space.OPLS4:改善化学空间挑战性领域的力场准确性。
J Chem Theory Comput. 2021 Jul 13;17(7):4291-4300. doi: 10.1021/acs.jctc.1c00302. Epub 2021 Jun 7.
9
Structure-activity relationships of Wee1 inhibitors: A review.Wee1 抑制剂的构效关系:综述。
Eur J Med Chem. 2020 Oct 1;203:112524. doi: 10.1016/j.ejmech.2020.112524. Epub 2020 Jul 10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验